ClinicalTrials.gg
RecruitingNCT07720141Updated Nov 17, 2026

Dissemination Of Lung Cancer Screening Education Through Tobacco Quitlines

An interventional study of High-touch strategy in Lung Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Prevention

How we know

Updated Nov 17, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 48 under way, 2 of them phase 3. Lung Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
3rd of 125
650 · median 40
Started
2026
with 1 other
No phase
28 of 162
10 open now
Primary completion
2032-06
later than 47 of 47 live
Registered
162nd of 162
by date

Among the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, this one is the 3rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 with no phase, reaches primary completion later than 47 of the 47 other live ones, and was the 162nd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

22 of the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The goal of this research study is to compare two different ways to increase lung cancer screening rates for tobacco quitline clients.

Read the detailed description

Primary Objective/Aim:

Aim 1. Compare two dissemination strategies that vary in intensity on demand for LCS. We hypothesize that there will be a higher demand for LCS in the high-touch strategy arm compared to the low-touch strategy arm, as demonstrated by self-reported LCS completion, as well as scheduling a visit with a health care provider to discuss LCS.

Secondary Objectives/Aim:

Aim 2. Evaluate the impact on reach of the high-touch and low-touch strategies to disseminate LCS educational materials (i.e., view of the decision aid or participation in a decision coaching visit). We expect that disseminating the LCS educational materials through the high-touch strategy will result in higher reach than delivering the LCS educational materials through the low-touch strategy.

Aim 3. Evaluate the financial sustainability and cost-effectiveness of the two approaches of disseminating LCS educational materials. We expect that the high-touch strategy will require a greater financial commitment and stronger partnerships between quitline service providers, state department of health, and health care systems, it will be a cost-effective dissemination strategy compared to the low-touch strategy (emailing/texting).

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Tobacco
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Quitline Client

Quitline client participants must meet the criteria for LCS with regards to age (50 to 80 years) and smoking history (20+ pack-years). This project will not re-confirm quitline client participant eligibility for screening. Tobacco treatment specialists will elicit study interest from only eligible quitline clients.

Representative of the Quitline Community

Representative of the Quitline Community will include any employee of the quitline service provider, representative from an organization that collaborates or funds a tobacco quitline, and/or a representative of the state department of health. All individuals will be adults (18 years and older) and able to speak English.

Representative of the Healthcare Sector

Representative of the healthcare sector will include any adult who works in healthcare, including but not limited to physicians, healthcare administrative leaders/managers, nurses, advanced practice providers. All individuals will be adults (18 years and older) and able to speak English.

Exclusion criteria

Exclusion Criteria:

Not applicable as our focus on quitline clients and representatives (adults) of the quitline community or the healthcare sector.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    CMP: Comparator - Low-Touch Strategy (Usual Practice): LCS Educational Resources

    Investigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients.

    Behavioral: High-touch strategy

  • Experimental
    INT: Intervention - High-Touch Strategy: LCS Educational Resources, Decision Coaching, Navigation

    Investigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients.

    Behavioral: High-touch strategy

Interventions

  • BehavioralHigh-touch strategy

    Participants will receive the LCS educational materials, decision coaching call for the SDM visit, and navigation for LCS.

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jun 2032, 67 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 67 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Start moved once since we started tracking on Sep 25, 2026: Jan 2027 → Nov 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartActual
Nov 4, 2026was Jan 2027
Primary completionEst.
Jun 30, 2032
CompletionEst.
Jun 30, 2034
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
UT MD Anderson is now Recruiting
Nov 17, 2026
Start date
Jan 1, 2027→Nov 4, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    UT MD Anderson is now Recruiting
    Start date Jan 1, 2027→Nov 4, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07720141
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Nov 4, 2026
Primary completion
Jun 30, 2032 (estimated)
Completion
Jun 30, 2034 (estimated)
Last update
Nov 17, 2026

Study contacts

Lisa Lowenstein, PHD
Contact
lmlowenstein@mdanderson.org
(713) 792-5807
Lisa Lowenstein, PHD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion